The estimated Net Worth of Keith A Kucinski is at least $1.11 Million dollars as of 22 November 2019. Mr. Kucinski owns over 94,500 units of Matinas Biopharma Inc stock worth over $334,058 and over the last 6 years he sold MTNB stock worth over $0. In addition, he makes $774,053 as Chief Financial Officer at Matinas Biopharma Inc.
Keith has made over 1 trades of the Matinas Biopharma Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 94,500 units of MTNB stock worth $115,290 on 22 November 2019.
The largest trade he's ever made was buying 94,500 units of Matinas Biopharma Inc stock on 22 November 2019 worth over $115,290. On average, Keith trades about 10,500 units every 0 days since 2019. As of 22 November 2019 he still owns at least 94,500 units of Matinas Biopharma Inc stock.
You can see the complete history of Mr. Kucinski stock trades at the bottom of the page.
Keith A. Kucinski serves as Chief Financial Officer of the Company. He most recently served as Chief Financial Officer at RemedyOne, a privately held healthcare consulting organization. Prior to that, he served as Vice President & Treasurer at Par Pharmaceutical Companies, Inc., an operating company of Endo International plc, a leading generics and specialty-branded pharmaceutical company. In addition, Mr. Kucinski held various roles at Barr Pharmaceuticals, Inc., including Senior Director, Finance & Corporate Development and Assistant Treasurer & Senior Director, Finance. Mr. Kucinski is a Certified Public Accountant. He received his Bachelor of Business Administration in Accounting from the University of Notre Dame and an M.B.A. in Finance & Management from the Leonard N. Stern School of Business at New York University.
As the Chief Financial Officer of Matinas Biopharma Inc, the total compensation of Keith Kucinski at Matinas Biopharma Inc is $774,053. There are 1 executives at Matinas Biopharma Inc getting paid more, with Jerome Jabbour having the highest compensation of $1,325,180.
Keith Kucinski is 50, he's been the Chief Financial Officer of Matinas Biopharma Inc since 2019. There are 14 older and 2 younger executives at Matinas Biopharma Inc. The oldest executive at Matinas Biopharma Holdings Inc is Herbert Conrad, 87, who is the Independent Chairman of the Board.
Keith's mailing address filed with the SEC is C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206 SOUTH SUITE 302, BEDMINSTER, NJ, 07921.
Over the last 8 years, insiders at Matinas Biopharma Inc have traded over $0 worth of Matinas Biopharma Inc stock and bought 1,157,037 units worth $1,139,222 . The most active insiders traders include Patrick G Lepore, Adam K Stern und James S Scibetta. On average, Matinas Biopharma Inc executives and independent directors trade stock every 40 days with the average trade being worth of $187,938. The most recent stock trade was executed by Adam K Stern on 21 August 2020, trading 20,000 units of MTNB stock currently worth $16,600.
matinas biopharma (nyse mkt: mtnb) is a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications. the company's proprietary, disruptive technology utilizes lipid-crystal nano-particle cochleates to nano-encapsulate existing drugs, making them safer, more tolerable, less toxic and orally bioavailable. the company's lead drug candidate mat2203, currently in phase 2, is an orally-administered, encochleated formulation of amphotericin b (a broad spectrum fungicidal agent). the company has an open investigational new drug (ind) application for mat2501, currently in phase 1, which is an orally-administered, encochleated formulation of amikacin (a broad spectrum aminoglycoside antibiotic agent) for acute bacterial infections, including non-tuberculous mycobacterium (ntm) and multi-drug resistant gram negative bacterial infections. the company's lead anti-infective product candidates, mat2203 and mat2501, position matinas biopharma to bec
Matinas Biopharma Inc executives and other stock owners filed with the SEC include: